JP Morgan Chase
ANTX icon

JP Morgan Chase’s AN2 Therapeutics ANTX Stock Holding History

JP Morgan Chase’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.2K Buy
+10,971
New +$47.2K ﹤0.01% 6383
2025
Q2 		– Sell
-49
Closed -$67 – 7045
2025
Q1 		$67 Sell
49
-3
-6% -$4 ﹤0.01% 6929
2024
Q4 		$72 Sell
52
-2
-4% -$2 ﹤0.01% 7060
2024
Q3 		$58 Sell
54
-966
-95% -$1.68K ﹤0.01% 7088
2024
Q2 		$2.19K Buy
+1,020
New +$2.43K ﹤0.01% 6514
2023
Q2 		– Sell
-8,511
Closed -$84K – 6896
2023
Q1 		$84K Buy
8,511
+2,247
+36% +$25K ﹤0.01% 5502
2022
Q4 		$60K Buy
6,264
+3,640
+139% +$48.7K ﹤0.01% 5553
2022
Q3 		$46K Buy
2,624
+145
+6% +$1.69K ﹤0.01% 5573
2022
Q2 		$19K Buy
+2,479
New +$32.8K ﹤0.01% 5902

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

JP Morgan Chase's ANTX Position: Q2 2026 in Review

JP Morgan Chase opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 10,971 shares worth $55.2K. The stake represents ﹤0.01% of the portfolio and ranks #6383 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in ANTX as recently as Q1 2025.

JP Morgan Chase first reported a position in ANTX in Q2 2022 and has held it in 9 quarters since. The position peaked at $84K in Q1 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • JP Morgan Chase held 10,971 shares of AN2 Therapeutics worth $55.2K as of Q2 2026.
  • AN2 Therapeutics was a new JP Morgan Chase position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6383 holding.
  • JP Morgan Chase first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 9 quarters since.
  • JP Morgan Chase's AN2 Therapeutics position peaked at $84K in Q1 2023.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.